Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Clusterin in disease pathology
TopicLeading institutions, researchers & key papers
This cluster of papers explores the multifaceted role of Clusterin, a chaperone protein, in cancer development, progression, and therapy. It investigates its involvement in apoptosis inhibition, TGF-ß signaling modulation, angiogenesis promotion, chemoresistance, and its potential as a biomarker for various cancers. The papers also discuss the implications of Clusterin in metastasis, particularly in prostate cancer.
37
Works
IDs:OpenAlex
How has Clusterin in disease pathology's publication output changed over time?
ScholarIQpublication output · 2009–2021
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2021.
1
1
2
1
1
1
200920112012201620202021
What are the most-cited papers on Clusterin in disease pathology?
ScholarIQmost cited works
Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis
Satoshi Serada, Minoru Fujimoto, Fumitaka Terabe, Hideki Iijima, Shinichiro Shinzaki, Shinya Matsuzaki, Tomoharu Ohkawara, Riichiro Nezu, Sachiko Nakajima, Taku Kobayashi, Scott E. Plevy, Tetsuo Takehara, Tetsuji Naka
S45123234. 2012230 CitationsOPEN ACCESS
iTRAQ-based proteomic identification of leucine-rich α-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases
Satoshi Serada, Minoru Fujimoto, Atsushi Ogata, Fumitaka Terabe, Toru Hirano, Hideki Iijima, Shinichiro Shinzaki, Teppei Nishikawa, Tomoharu Ohkawara, Kota Iwahori, Nobuyuki Ohguro, T Kishimoto, Tetsuji Naka
Annals of the Rheumatic Diseases. 2009222 Citations
Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis
Shinichiro Shinzaki, Katsuyoshi Matsuoka, Hideki Iijima, Shinta Mizuno, Satoshi Serada, Minoru Fujimoto, Norimitsu Arai, Noriyuki Koyama, Eiichi Morii, Mamoru Watanabe, Toshifumi Hibi∥, Takanori Kanai∥, Tetsuo Takehara, Tetsuji Naka
Journal of Crohn s and Colitis. 2016156 CitationsOPEN ACCESS
Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease
Eriko Yasutomi, Toshihiro Inokuchi, Sakiko Hiraoka, Kensuke Takei, Shoko Igawa, Shumpei Yamamoto, Masayasu Ohmori, Shohei Oka, Yasushi Yamasaki, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, Masaki Furukawa, Kouichi Itoshima, Ken Okada, Fumio Otsuka, Takehiro Tanaka, Toshiharu Mitsuhashi, Jun Kato, Hiroyuki Okada
Scientific Reports. 202184 CitationsOPEN ACCESS
Temperature-Sensitive Polymer-Coated Magnetic Nanoparticles as a Potential Drug Delivery System for Targeted Therapy of Thyroid Cancer
Bhanu Koppolu, Zarna Bhavsar, Aniket S. Wadajkar, Sivaniarvindpriya Nattama, Maham Rahimi, Fiemu E. Nwariaku, Kytai T. Nguyen
S15497777. 201263 Citations
Where is Clusterin in disease pathology research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
S45123234230
S1549777763
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Clusterin in disease pathology is open access?
ScholarIQopen access share
57%OPEN ACCESS
Gold
14%
Green
0%
Hybrid
29%
Bronze
14%
Closed
43%
Related on ScholarIQ
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Paper
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Paper
Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy
Paper
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Paper
Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer
Paper
Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness
Paper